TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8959161

Group type: EXPERIMENTAL
Intervention: 1 mmol MgCl2 (low)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mmol MgCl2 (high)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 mmol MgCl2 (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A23187 with 1 mmol MgCl2 (low)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A23187 with 10 mmol MgCl2 (high)
Number of subjects: 0

Group type: COMPARATOR
Intervention: A23187 with 0 mmol MgCl2 (control)
Number of subjects: 0
Study: 1396643

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 14
Study: 2933253

Group type: EXPERIMENTAL
Intervention: 10 mg ketanserin
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10 ml saline (placebo)
Number of subjects: 20
Study: 30443883

Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT) plus exercise
Number of subjects: 84

Group type: COMPARATOR
Intervention: Ultrasound (US) treatment and Transcutaneous Nerve Stimulation (TENS) plus exercise
Number of subjects: 84
Study: 27498173

Group type: EXPERIMENTAL
Intervention: Coaching group (verbal encouragement and visual cue)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-coaching group (no coaching)
Number of subjects: 30
Study: 26063002

Group type: EXPERIMENTAL
Intervention: Quaternary ammonium compound-based sanitizing wipe used at least once per day
Number of subjects: 5
Study: 23222844

Group type: EXPERIMENTAL
Intervention: Paced respiration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control (fast, shallow breathing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 21727151

Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous exercise (MICE) at 70% of the maximal HR of the graded maximal exercise test (n=10)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MICE at the maximal 6MWT HR (n=8)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT) based on the 6MWT and the 200-mFWT maximal HR (n=9)
Number of subjects: 27
Study: 19794123

Group type: COMPARATOR
Intervention: Placebo (in a 14-month trial of oral glatiramer acetate)
Number of subjects: 906

Group type: COMPARATOR
Intervention: Placebo (in a 3-year trial of interferon beta-1b)
Number of subjects: 906

Group type: COMPARATOR
Intervention: Placebo (in both trials)
Number of subjects: 906
Study: 16488348

Group type: EXPERIMENTAL
Intervention: Supportive intervention including an information pack and Fatigue Diary, monthly support nurse visits for three months
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Supportive intervention
Number of subjects: 103
Study: 12892594

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g intravenously 0.5 - 1 h prior to operation)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Cefuroxime (0.75 g preoperatively and the same dose q8h for 3 d)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 305

Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 305
Study: 11049007

Group type: EXPERIMENTAL
Intervention: Ibuprofen gel
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9349064

Group type: EXPERIMENTAL
Intervention: Nebulised lignocaine (4 ml 4% lignocaine)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nebulised saline (4 ml 0.9% NaCl)
Number of subjects: 75
Study: 8260897

Group type: EXPERIMENTAL
Intervention: rhGM-CSF (125 micrograms/m2/day) for 14 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 62
Study: 3845028

Group type: EXPERIMENTAL
Intervention: 0.05 mg Sulprostone gel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.1 mg Sulprostone gel
Number of subjects: 40
Study: 31683351

Group type: EXPERIMENTAL
Intervention: Double Vertical Loop (DVL) suture configuration
Number of subjects: 22

Group type: COMPARATOR
Intervention: Single Vertical Loop (SVL) suture configuration
Number of subjects: 22
Study: 29452809

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sevoflurane with remifentanil
Number of subjects: 36
Study: 28060360

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 72

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 72
Study: 26523885

Group type: EXPERIMENTAL
Intervention: 7-module internet-delivered cognitive behavioral therapy (iCBT) program
Number of subjects: 96

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 96
Study: 23348981

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (3000 mg per day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 26
Study: 21511500

Group type: EXPERIMENTAL
Intervention: EMONO inhalation
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 17973947

Group type: EXPERIMENTAL
Intervention: HRT‐MPA (conjugated oestrogen plus medroxyprogesterone acetate)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: HRT‐NET (conjugated oestrogen plus norethisterone)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 104
Study: 16472368

Group type: EXPERIMENTAL
Intervention: Community-based program including depression screening and group activity
Number of subjects: 1685

Group type: COMPARATOR
Intervention: Control group (historical trend)
Number of subjects: 1685
Study: 12862363

Group type: COMPARATOR
Intervention: Cyclical etidronate (200 mg daily for 2 weeks every 3 months) for 18 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate for 12 months followed by alendronate (5 mg daily) for 6 months
Number of subjects: 40
Study: 10547251

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (Augmentin) 45 mg/kg/d in 2 divided doses for 10 days
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Azithromycin (Zithromax), 10 mg/kg on the first day, followed by 5 mg/kg daily for 4 days
Number of subjects: 106

Group type: COMPARATOR
Intervention: Both interventions (Amoxicillin/clavulanate and Azithromycin)
Number of subjects: 106
Study: 8921795

Group type: EXPERIMENTAL
Intervention: 130-J truncated biphasic waveform
Number of subjects: 294

Group type: COMPARATOR
Intervention: 200-J damped sine wave monophasic waveform
Number of subjects: 294
Study: 1885826

Group type: EXPERIMENTAL
Intervention: Topical 2% lidocaine jelly
Number of subjects: 0
Study: 6889218

Group type: EXPERIMENTAL
Intervention: Combined therapy (propranolol + nifedipine)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nifedipine alone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nifedipine monotherapy
Number of subjects: 26
Study: 31690151

Group type: EXPERIMENTAL
Intervention: Intra-saccular flow diversion (ISFD) using the Woven Endo-Bridge (WEB) device
Number of subjects: 250

Group type: COMPARATOR
Intervention: Best conventional management option (surgical or endovascular)
Number of subjects: 250
Study: 29898352

Group type: EXPERIMENTAL
Intervention: Peer group education by trained former patients
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine instructions by department's nurses
Number of subjects: 70
Study: 26679079

Group type: EXPERIMENTAL
Intervention: Extended-release (ER) niacin
Number of subjects: 12
Study: 24408212

Group type: EXPERIMENTAL
Intervention: Varenicline (active medication)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 88
Study: 22200391

Group type: EXPERIMENTAL
Intervention: Mechanically imposed stiff-knee gait (SKG-M) using a lockable knee brace
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physiologically imposed stiff-knee gait (SKG-P) using electrical stimulation to the quadriceps
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physiologically imposed stiff-knee gait (SKG-P)
Number of subjects: 20
Study: 20028707

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg, once daily
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Fingolimod 5.0 mg, once daily (switched to 1.25 mg during months 15-24)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Fingolimod (both doses)
Number of subjects: 250
Study: 16871270

Group type: EXPERIMENTAL
Intervention: Open-label sildenafil (50 mg adjustable to 100 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (initial treatment)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sildenafil (initial treatment)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Open-label sildenafil
Number of subjects: 50
Study: 16338916

Group type: EXPERIMENTAL
Intervention: No or low risk of self-harm based on suicidal ideation assessment
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Intermediate risk of self-harm based on suicidal ideation assessment
Number of subjects: 761

Group type: EXPERIMENTAL
Intervention: Initial assessment of suicidal ideation
Number of subjects: 761
Study: 12015689

Group type: EXPERIMENTAL
Intervention: Cefazolin (2 g iv) plus probenecid (1 g by mouth)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Ceftriaxone (1 g iv) plus oral placebo
Number of subjects: 116
Study: 10506666

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing-hormone (CRH) 100 microg (i.v.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing-hormone (CRH) with pre-treatment with dexamethasone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7542982

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration (0.03 mg.kg‐1 body wt.day‐1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration
Number of subjects: 9
Study: 1955994

Group type: EXPERIMENTAL
Intervention: 4.0 mm incision (foldable IOL)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: 5.2 mm incision (PMMA IOL)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: 7.0 mm incision (PMMA IOL)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Cold versus warm balanced salt solution irrigation
Number of subjects: 500

Group type: COMPARATOR
Intervention: Scleral cautery (complete to limbus vs. posterior to Tenon's fascia)
Number of subjects: 500
Study: 7083463

Group type: EXPERIMENTAL
Intervention: Intermittent bolus - 50-70 mg/m2/day over 1 h daily for 5 days (39 patients)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Infusion - 50-70 mg/m2/day as a continuous infusion for 5 days (38 patients)
Number of subjects: 77
Study: 31139827

Group type: EXPERIMENTAL
Intervention: Multiprofessional preventive home visits
Number of subjects: 422

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 422
Study: 31072414

Group type: EXPERIMENTAL
Intervention: 5% O2 group (benchtop incubator)
Number of subjects: 230
Study: 27831907

Group type: EXPERIMENTAL
Intervention: Visual feedback on compression rate
Number of subjects: 50

Group type: COMPARATOR
Intervention: No visual feedback
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Visual feedback on compression force
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 50
Study: 26254087

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) 3.8g/day for 9 months
Number of subjects: 133

Group type: COMPARATOR
Intervention: Sunflower oil (SO)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 133
Study: 24134527

Group type: EXPERIMENTAL
Intervention: Maternal mid-pregnancy 25-hydroxyvitamin D level (mean 73.7 nmol/L)
Number of subjects: 1248
Study: 21719412

Group type: EXPERIMENTAL
Intervention: Online personalized feedback intervention
Number of subjects: 450

Group type: COMPARATOR
Intervention: Information-only control condition
Number of subjects: 450
Study: 19428899

Group type: EXPERIMENTAL
Intervention: Vitamin A Supplementation (VAS)
Number of subjects: 0
Study: 17234331

Group type: EXPERIMENTAL
Intervention: Obtape
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: DUPS
Number of subjects: 190

Group type: COMPARATOR
Intervention: TVT
Number of subjects: 190
Study: 15799918

Group type: EXPERIMENTAL
Intervention: Aortic connector device (ACD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hand-sewn grafts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of platelet hyperreactivity, marginal graft flow, and endothelial disease
Number of subjects: 0
Study: 10924781

Group type: EXPERIMENTAL
Intervention: 6 EU vaccine
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: 12 EU vaccine
Number of subjects: 242

Group type: COMPARATOR
Intervention: Reference vaccine
Number of subjects: 242
Study: 8931413

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. (group I)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg t.i.d. (group II) plus amoxicillin 750 mg t.i.d. for 14 days
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. plus amoxicillin 750 mg t.i.d. and metronidazole 500 mg t.i.d. for 14 days (group III)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. plus clarithromycin 500 mg t.i.d. for 14 days (group IV)
Number of subjects: 53
Study: 1524686

Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste plus AmF/SnF2 mouthwash
Number of subjects: 44
Study: 4017156

Group type: EXPERIMENTAL
Intervention: Intensity expressed relative to ventilation thresholds (VT1 and VT2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Traditional expression of intensity relative to VO2max
Number of subjects: 16
Study: 3597990

Group type: EXPERIMENTAL
Intervention: d-sotalol (1, 1.5 or 2 mg/kg body weight)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: d,l-sotalol (1 mg/kg)
Number of subjects: 20
Study: 29693228

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NC)
Number of subjects: 13939
Study: 29132404

Group type: EXPERIMENTAL
Intervention: 10 μg FP-1201-lyo administered intravenously once daily for 6 days
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo administered intravenously once daily for 6 days
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 10 μg FP-1201-lyo
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 26314817

Group type: EXPERIMENTAL
Intervention: Fp MDPI 800 μg (400 μg/inhalation × 2 inhalations)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fp DPI 1000 μg (250 μg/inhalation × 4 inhalations)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fp MDI 880 μg (220 μg/inhalation × 4 inhalations)
Number of subjects: 18
Study: 22593230

Group type: EXPERIMENTAL
Intervention: Rotating-shift group (experimental group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Fixed-day-shift group (control group)
Number of subjects: 62
Study: 21918240

Group type: EXPERIMENTAL
Intervention: Peer-delivered, theory-based support for physical activity behavior change
Number of subjects: 81

Group type: COMPARATOR
Intervention: Basic education, gym membership, and pedometer for self-monitoring (control group)
Number of subjects: 81
Study: 18513638

Group type: EXPERIMENTAL
Intervention: Regadenoson
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 17154785

Group type: EXPERIMENTAL
Intervention: Action gaming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nongamers
Number of subjects: 0
Study: 12556736

Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 0
Study: 10898419

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (1,000 IU for three months)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 8809957

Group type: EXPERIMENTAL
Intervention: Platelet alloantibodies to human platelet antigens (HPA) -1, -3 and -5
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Platelet alloantibodies in patients with HLA-antibodies
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Presence of antibody prior to transfusions
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: HLA-antibodies reacting with over 95% of unselected lymphocytes
Number of subjects: 59
Study: 1331023

Group type: EXPERIMENTAL
Intervention: ORG 2766 (40 mg/day for 8 weeks)
Number of subjects: 20
Study: 3914177

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 29397214

Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 199

Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 199
Study: 27058909

Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation (VNS)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Continued medical therapy (control)
Number of subjects: 707
Study: 24688260

Group type: EXPERIMENTAL
Intervention: ImageJ evaluation of optic disc pallor
Number of subjects: 35
Study: 22986318

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) lidocaine 1.5 mg/kg 20 minutes before incision followed by a continuous lidocaine infusion of 1.5 mg/kg/hr until the end of surgery
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline in a similar manner (control group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) lidocaine
Number of subjects: 48
Study: 20520820

Group type: EXPERIMENTAL
Intervention: Transcutaneous application of inactivated influenza vaccine (TETAGRIP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intramuscular (IM) immunization with inactivated influenza vaccine (TETAGRIP)
Number of subjects: 36
Study: 18442338

Group type: EXPERIMENTAL
Intervention: Dietary intervention for never smokers
Number of subjects: 2066

Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 2066
Study: 16039487

Group type: EXPERIMENTAL
Intervention: Temporal hinge LASIK
Number of subjects: 24

Group type: COMPARATOR
Intervention: Superior hinge LASIK
Number of subjects: 24
Study: 12455077

Group type: EXPERIMENTAL
Intervention: Verapamil (1 mg over 2 min) administered via an infusion catheter distal to the angioplasty site.
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (7 patients with AMI and TIMI grade 3 flow).
Number of subjects: 212
Study: 10793956

Group type: EXPERIMENTAL
Intervention: Realtime teledermatology
Number of subjects: 204

Group type: COMPARATOR
Intervention: Conventional outpatient consultation
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Store-and-forward teledermatology
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Cost analysis of realtime teledermatology
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Cost analysis of store-and-forward teledermatology
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis of realtime teledermatology
Number of subjects: 204
Study: 8969027

Group type: EXPERIMENTAL
Intervention: Papaverine administered intraluminally, retrograde in the internal mammary artery
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Papaverine administered topically
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Papaverine administered perivascularly in the pedicle
Number of subjects: 106
Study: 1569444

Group type: EXPERIMENTAL
Intervention: Cisplatin-cyclophosphamide (75 mg/m2 and 600 mg/m2)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Carboplatin-cyclophosphamide (300 mg/m2 and 600 mg/m2)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Cisplatin-cyclophosphamide
Number of subjects: 447

Group type: COMPARATOR
Intervention: Carboplatin-cyclophosphamide
Number of subjects: 447
Study: 3885884

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg every 6 hours for one week)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 31112554

Group type: EXPERIMENTAL
Intervention: BCI-based attention training program (3 sessions per week for 8 weeks, followed by 3 sessions per month for 12 weeks)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Waitlist-control group (received similar 20-week intervention after an 8-week wait)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Pooled group (after full 20-week treatment)
Number of subjects: 172
Study: 29615645

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 280
Study: 26949378

Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate-carbohydrate beverage (PRO-CHO, 14 g protein/h and 69 g CHO/h)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isocaloric carbohydrate beverage (CHO, 84 g/h)
Number of subjects: 18
Study: 25557316

Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU cholecalciferol daily)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Vitamin D (600 IU daily)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Vitamin D (1200 IU daily)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control (placebo) in study 2
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control (placebo) in study 3
Number of subjects: 184
Study: 24304745

Group type: EXPERIMENTAL
Intervention: Working memory training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo version of the working memory training program
Number of subjects: 0
Study: 19351798

Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 18156921

Group type: EXPERIMENTAL
Intervention: Division of short gastric vessels
Number of subjects: 102

Group type: COMPARATOR
Intervention: Non-division of short gastric vessels
Number of subjects: 102
Study: 15985295

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 64
Study: 12973482

Group type: EXPERIMENTAL
Intervention: Gentamicin at a dose of 4 mg/kg every 24 hours (protocol group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gentamicin at a dose of 2.5 mg/kg every 12 hours (control group)
Number of subjects: 100
Study: 10338171

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 1 mg morphine sulfate (MS)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 3 mg MS
Number of subjects: 79

Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 79

Group type: COMPARATOR
Intervention: 1 mg MS in saline
Number of subjects: 79

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 79
Study: 8717567

Group type: COMPARATOR
Intervention: Intramuscular injection of 0.5 mg of Syntometrine
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 125 ug of prostaglandin 15‐methyl F2 alpha
Number of subjects: 112
Study: 1828508

Group type: EXPERIMENTAL
Intervention: Couple therapy (T) group, N = 33
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (C) group, N = 30
Number of subjects: 63